The Avicena Group of Palo Alto, CA, says its Phase III trial of ALS-02 for Lou Gehrig's disease failed to demonstrate a benefit over placebos. But researchers noted that data analysis demonstrated "a positive trend toward decreased mortality in subjects receiving ALS-02."
"We are very interested in further exploring this trend toward decreased mortality," said Belinda Tsao-Nivaggioli, Ph.D., Avicena's CEO. "We intend to explore whether these findings can be expected to impact the remaining regulatory path for the compound."
- here's the release for more information